Form 4: Neumora Therapeutics Stockholders Approve Director's Option Repricing to Boost Incentives

Neumora Therapeutics, Inc. announced that its stockholders approved the repricing of stock options for Director David Piacquad and other insiders, significantly lowering the exercise price to $0.72 per share.

Summary

• On May 28, 2025, Neumora Therapeutics, Inc. (NMRA) stockholders approved the repricing of outstanding stock options held by members of the Board, certain employees, and other service providers, including Director David Piacquad.
• The exercise price for these options was repriced from $1.69 per share to $0.72 per share.
• The repricing is contingent on the reporting person, David Piacquad, remaining in service to the Issuer through August 13, 2026.
• Specifically, 46,455 stock options with an original exercise price of $1.69 were repriced to $0.72. These options vest 1/36th monthly from September 8, 2023, fully vesting by September 8, 2026, and expire on September 14, 2033.
• Another 28,571 stock options, originally priced at $1.69, were repriced to $0.72. These vest on the earlier of the one-year anniversary of June 13, 2024, or immediately prior to the next Annual Meeting following June 13, 2024, and expire on June 13, 2034.
• Additionally, 80,000 new stock options were acquired at an exercise price of $0.72. These options vest on the earlier of the one-year anniversary of May 28, 2025, or immediately prior to the next Annual Meeting following May 28, 2025, and expire on May 27, 2035.
• Following these transactions, Director David Piacquad beneficially owns a total of 155,026 stock options at an exercise price of $0.72.

Sentiment

Score: 6

Explanation: The repricing of options is a mixed signal. While it's positive for executive retention and motivation, it implies past stock underperformance. The shareholder approval and new grants add a positive layer of commitment, but the underlying reason for repricing is a negative.

Positives

• The repricing of stock options to a lower exercise price of $0.72 per share provides a significant incentive for Director David Piacquad and other key personnel, potentially increasing their motivation and alignment with shareholder interests.
• Shareholder approval of the repricing indicates a collective belief in the long-term value and potential of the company, as it aims to retain and incentivize critical talent.
• The new grant of 80,000 stock options at the repriced rate further strengthens the incentive structure for the director.

Negatives

• Stock option repricing can be viewed negatively by some investors as it dilutes existing shareholder value by effectively granting new options at a lower price, especially if the original options were underwater due to poor stock performance.
• The repricing suggests that the company's stock price has performed poorly enough to render previous options out-of-the-money, necessitating this action to retain and motivate executives.

Risks

• The repricing is subject to the reporting person remaining in service to the Issuer through August 13, 2026, posing a risk if the individual departs before this date, potentially impacting the intended incentive.
• Continued poor stock performance could lead to further repricing or a lack of motivation even with the repriced options, if the stock price remains below the new exercise price.
• Potential shareholder dissatisfaction or legal challenges related to the repricing, especially if not perceived as being in the best interest of all shareholders.

Future Outlook

The repricing and new grant of stock options are intended to re-incentivize key personnel, including Director David Piacquad, by aligning their compensation more closely with current market conditions and future stock performance. This move aims to retain talent and motivate them towards achieving future company milestones, with the expectation that a lower exercise price will make the options more valuable and exercisable.

Management Comments

• On May 28, 2025, the Issuer's stockholders approved the repricing of the option.
• On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share of the outstanding stock options held by members of the Board, certain employees and other service providers.
• The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.

Industry Context

Stock option repricing is a practice often employed by companies, particularly in the biotechnology or early-stage growth sectors, when their stock price has significantly declined, rendering previously granted options 'underwater' (i.e., the exercise price is higher than the current market price). This action is typically taken to re-motivate and retain key talent who might otherwise leave due to a lack of incentive from their equity compensation. While common, it can be viewed critically by investors as it effectively resets the bar for executive compensation at a lower level, potentially signaling past underperformance.

Comparison to Industry Standards

• Option repricing is a common practice in industries with volatile stock performance, such as biotechnology, where companies like Moderna (MRNA) or BioNTech (BNTX) have faced periods of significant stock price fluctuations. While specific repricing events are less frequently publicized for large, established biotechs, smaller or clinical-stage companies often resort to this to retain talent.
• The condition of continued service (through August 13, 2026) is a standard retention mechanism often tied to repriced options or new grants, similar to practices seen at companies like Sarepta Therapeutics (SRPT) or Alnylam Pharmaceuticals (ALNY) when incentivizing long-term commitment from key executives.
• The vesting schedules (e.g., 1/36th monthly or one-year anniversary/next annual meeting) are typical for long-term incentive plans across various industries, including tech companies like Salesforce (CRM) or Adobe (ADBE), aiming to align executive interests with sustained company performance.

Corporate Governance

Stakeholder Impact

• **Shareholders:** Potential dilution from the repricing of options, but also potential benefit from increased executive motivation and retention, which could lead to improved company performance. The approval by stockholders suggests a belief in the long-term benefits.
• **Employees/Management:** Direct positive impact through re-incentivized equity compensation, making their stock options more valuable and providing a stronger financial incentive to remain with the company and drive its success.

Next Steps

• David Piacquad must remain in service to Neumora Therapeutics, Inc. through August 13, 2026, for the repricing to remain effective.
• The various tranches of stock options will continue to vest according to their respective schedules (e.g., monthly vesting for some, or based on anniversaries/annual meetings for others).

Key Dates

Recommendation

Keywords

Neumora Therapeutics, NMRA, Stock Options, Option Repricing, SEC Form 4, Insider Trading, Executive Compensation, Corporate Governance, Director Compensation, Equity Incentives